Key Highlights

● Structure Therapeutics closed at $32.69 on Tuesday, September 29, down 6.77% from the prior close of $35.07.

● Aleniglipron, an oral GLP-1 candidate for obesity and type 2 diabetes, has shown weight loss of up to about 16%.

● The shares closed well below their 50-day average of $46.25 and within a 52-week range of $24.63 to $94.90.

● It reported a second-quarter loss of $0.49 per share on August 6 and reports next on November 5.

Structure Therapeutics Inc. (NASDAQ:GPCR) shed 6.77% on Tuesday, September 29, 2026, ending the session at $32.69 after a prior close of $35.07. The clinical-stage biopharmaceutical company was among the steeper decliners in the US market while the S&P 500 slipped 0.17% to 7,670.84. Trading Volume during the session ran well below the stock's average.

The Company and Its Lead Programs

Structure Therapeutics develops oral medicines for chronic diseases. Its lead candidate, aleniglipron, is an oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. The company has reported weight loss of up to about 16% with the drug, and a Phase 3 program is underway. A second program, ACCG-2671, is an amylin agonist.

GLP-1 drugs are a central class in obesity treatment, and most marketed versions are injected rather than taken by mouth, which is the gap an oral candidate is designed to address.

Recent Results

Structure reported second-quarter results on August 6, with a loss of $0.49 per share against a consensus estimate of a $0.39 loss. Over the trailing twelve months, the net loss was $214.84 million. As a clinical-stage company, Structure has no product revenue, and its results reflect the cost of running late-stage trials.

How the Shares Have Traded

At $32.69, the stock closed below both its 50-day Moving Average of about $46.25 and its 200-day moving average of about $46.43. The 52-week range runs from $24.63 to $94.90, so the shares finished about 66% below their yearly high and about 33% above the low. Analyst consensus is Moderate Buy, with two Strong Buy, twelve Buy, one Hold and two Sell ratings.

A Clinical-Stage Story With Phase 3 Ahead

The next Quarterly Report is expected on November 5. With aleniglipron in Phase 3 development, the company's near-term story rests on trial progress rather than product revenue.